Allen Institute for Artificial Intelligence
supp.ai logo
supp.ai

Discover Supplement-Drug Interactions

Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: 3 years ago

Possible Interaction: Scopolamine and Huperzine A

supplement:

Huperzine A

Research Papers that Mention the Interaction

Scopolamine reversed the effect of huperzine‐A on morphine‐induced expression of sensitization.
The results showed that: (a) the muscarinic receptor antagonist scopolamine (10.8 &mgr;g/rat) microinjected into the NAc shell blocked expression of … not scopolamine (10.8 &mgr;g/rat), microinjected into the NAc shell blocked morphine‐induced expression of sensitization; and (c) pre‐infusion of scopolamine (… huperzine‐A (….
European journal of pharmacology  •  2018  |  View Paper
Scopolamine (0.05mg/kg) which did not affect the locomotor activity when …, but not mecamylamine (1mg/kg), reversed the acute attenuation effect of huperzine A (0.4mg/kg) on morphine-induced locomotor activity at the acquisition stage … the inhibition of huperzine A on the expression of morphine-induced sensitization.
Pharmacology Biochemistry and Behavior  •  2017  |  View Paper
Huperzine A (25 ng), injected intracranially 15 min before training, reversed memory deficits induced by scopolamine and muscimol at 30 min after training, and this reversal persisted at least 1 h. The improving effects of huperzine A exhibited a bell-shaped dose-response curve.
Acta pharmacologica Sinica  •  2000  |  View Paper
The results demonstrated that huperzine A was the most selective acetylcholinterase inhibitor, and improved the working memory deficit induced by scopolamine significantly better than did E2020 or tacrine, suggesting it may be a promising agent for clinical therapy of cognitive impairment in patients with Alzheimer's Disease.
Neuroreport  •  1996  |  View Paper
Scopolamine (Scop, 0.2 mg/kg iv) reversed significantly these effects of Hup-A (10 micrograms/rabbit, icv), but Scop butylbromide (0.4 mg/kg, iv) which can not pass the blood-brain barrier did not.
Zhongguo yao li xue bao = Acta pharmacologica Sinica  •  1989  |  View Paper